These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

184 related items for PubMed ID: 22873622

  • 1. Sorafenib use in hepatocellular carcinoma in Japan: early experience and impact on clinical practice.
    Zhu AX.
    Clin Drug Investig; 2012 Aug 08; 32 Suppl 2():1-2. PubMed ID: 22873622
    [No Abstract] [Full Text] [Related]

  • 2. Sorafenib in hepatocellular carcinoma.
    Josephs DH, Ross PJ.
    Br J Hosp Med (Lond); 2010 Aug 08; 71(8):451-6. PubMed ID: 20852487
    [Abstract] [Full Text] [Related]

  • 3. Sorafenib, a systemic therapy for hepatocellular carcinoma.
    Méndez-Sánchez N, Vásquez-Fernández F, Zamora-Valdés D, Uribe M.
    Ann Hepatol; 2008 Aug 08; 7(1):46-51. PubMed ID: 18376365
    [Abstract] [Full Text] [Related]

  • 4. Sorafenib therapy in patients with hepatocellular carcinoma before liver transplantation.
    Rowe IA.
    Hepatology; 2010 Sep 08; 52(3):1171-2. PubMed ID: 20812364
    [No Abstract] [Full Text] [Related]

  • 5. Target therapy for hepatocellular carcinoma: is sorafenib for everybody?
    Daniele B, Di Maio M.
    J Clin Gastroenterol; 2009 Sep 08; 43(5):389-90. PubMed ID: 19564813
    [No Abstract] [Full Text] [Related]

  • 6. Sequential therapy with sunitinib and sorafenib in metastatic hepatocellular carcinoma.
    Ahn HK, Lee S, Sun JM, Lee J, Park SH, Park JO, Park YS, Kang WK, Lim HY.
    Invest New Drugs; 2012 Aug 08; 30(4):1768-72. PubMed ID: 21720741
    [No Abstract] [Full Text] [Related]

  • 7. Hepatocellular carcinoma: sorafenib before liver transplantation?
    Braillon A.
    Hepatology; 2010 Jun 08; 51(6):2232-3. PubMed ID: 20041410
    [No Abstract] [Full Text] [Related]

  • 8. Sorafenib for liver cancer: the horizon broadens.
    Johnson P, Billingham L.
    Lancet Oncol; 2009 Jan 08; 10(1):4-5. PubMed ID: 19111238
    [No Abstract] [Full Text] [Related]

  • 9. Sorafenib for HCC: a pragmatic perspective.
    Razumilava N, Gores GJ.
    Oncology (Williston Park); 2011 Mar 08; 25(3):300, 302. PubMed ID: 21548475
    [No Abstract] [Full Text] [Related]

  • 10. Candidacy for sorafenib in HCC patients: is there a slippery slope beyond a SHARP edge?
    Burak KW.
    Oncology (Williston Park); 2011 Mar 08; 25(3):296, 298, 300. PubMed ID: 21548474
    [No Abstract] [Full Text] [Related]

  • 11. Health-related quality of life and sorafenib.
    Spinzi G, Terreni N.
    Hepatology; 2010 Oct 08; 52(4):1523. PubMed ID: 20672386
    [No Abstract] [Full Text] [Related]

  • 12. Fatal hemobilia in advanced hepatocellular carcinoma invading biliary tract after treatment with sorafenib and biliary stenting.
    Verset G, Maréchal R, Bali MA, Devière J, Van Laethem JL.
    Ann Oncol; 2010 Jun 08; 21(6):1381-1382. PubMed ID: 20332137
    [No Abstract] [Full Text] [Related]

  • 13. [Sorafenib for the treatment of HCC--the beginning of a new era in the treatment of HCC].
    Greten TF, Manns MP, Malek N.
    Z Gastroenterol; 2009 Jan 08; 47(1):55-60. PubMed ID: 19156592
    [Abstract] [Full Text] [Related]

  • 14. Commentary: Sorafenib use in patients with advanced hepatocellular carcinoma and underlying Child-Pugh B cirrhosis: evidence and controversy.
    Zhu AX, Clark JW.
    Oncologist; 2009 Jan 08; 14(1):67-9. PubMed ID: 19147690
    [No Abstract] [Full Text] [Related]

  • 15. Commentary: Sorafenib -- the end of a long journey in search of systemic therapy for hepatocellular carcinoma, or the beginning?
    Abou-Alfa GK.
    Oncologist; 2009 Jan 08; 14(1):92-4. PubMed ID: 19144679
    [No Abstract] [Full Text] [Related]

  • 16. Efficacy and safety of sorafenib in advanced hepatocellular carcinoma under daily practice conditions.
    Welker MW, Lubomierski N, Gog C, Herrmann E, Engels K, Vogl TJ, Bechstein WO, Zeuzem S, Trojan J.
    J Chemother; 2010 Jun 08; 22(3):205-11. PubMed ID: 20566428
    [Abstract] [Full Text] [Related]

  • 17. [Our experience of the treatment with sorafenib for unresectable hepatocellular carcinoma].
    Ishizaki M, Kaibori M, Matsui K, Nakatake R, Matsushima H, Sakaguchi T, Kwon AH.
    Gan To Kagaku Ryoho; 2011 Nov 08; 38(12):2493-5. PubMed ID: 22202424
    [Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19. [Hepatocellular carcinoma].
    Yamashita T, Arai K, Kaneko S.
    Nihon Rinsho; 2010 Oct 08; 68(10):1861-5. PubMed ID: 20954330
    [Abstract] [Full Text] [Related]

  • 20. Current status of hepatocellular carcinoma treatment in Japan: case study and discussion-voting system.
    Kudo M, Tateishi R, Yamashita T, Ikeda M, Furuse J, Ikeda K, Kokudo N, Izumi N, Matsui O.
    Clin Drug Investig; 2012 Aug 08; 32 Suppl 2():37-51. PubMed ID: 22873626
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 10.